CAU
NAGE

Caxton Associates (UK)’s Niagen Bioscience NAGE Stock Holding History

Caxton Associates (UK)’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-29,328
Closed -$274K – 1006
2025
Q3 		$274K Buy
29,328
+4,160
+17% +$42K 0.01% 566
2025
Q2 		$363K Buy
+25,168
New +$249K 0.01% 503

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Caxton Associates (UK)'s NAGE Position: Q4 2025 in Review

Caxton Associates (UK) sold out of Niagen Bioscience (NAGE) in Q4 2025, closing a stake of 29,328 shares — an estimated $274K sold.

Caxton Associates (UK) first reported a position in NAGE in Q2 2025 and held it in 2 quarters. The position peaked at $363K in Q2 2025. 169 funds tracked by Wall St. Rank hold NAGE as of Q4 2025.

  • Caxton Associates (UK) reported no remaining Niagen Bioscience position as of Q4 2025 after selling out during the quarter.
  • Caxton Associates (UK) sold 29,328 Niagen Bioscience shares in Q4 2025, an estimated $274K.
  • Caxton Associates (UK) first reported a position in Niagen Bioscience in Q2 2025 and held it in 2 quarters.
  • Caxton Associates (UK)'s Niagen Bioscience position peaked at $363K in Q2 2025.
  • 169 funds tracked by Wall St. Rank held Niagen Bioscience as of Q4 2025.

Based on Caxton Associates (UK)'s 13F filing for Q4 2025, filed 13 Feb 2026.